Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715078 · ClinicalTrials.gov registry record · Phase 2
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
A Phase 2 study, sponsored by Dendreon.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT00715078 is a Phase 2 study that has completed, run by Dendreon. The registered enrollment target is 122 participants.
The verdict
NCT00715078, a Phase 2 study, has completed, sponsored by Dendreon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen
Interventions
- BIOLOGICAL sipuleucel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2008-10 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00715078
The ClinicalTrials.gov registry entry for NCT00715078 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dendreon, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sipuleucel-T is the first listed.
NCT00715078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00715078 about?
NCT00715078 is a clinical study titled "To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen". This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen
What is the current status of trial NCT00715078?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2008-10. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00715078?
The interventions under investigation include: sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT00715078?
This trial is sponsored by Dendreon, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.